2-(4-NITROPHENYL)-6-[(2S,5S)-5-HYDROXYMETHYLOXOLAN-2-YL]-5,6-DIHYDRO[1,3]-DIAZOLO[1,2-C][1,3]DIAZIN-5-ONE | 348597-64-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(4-NITROPHENYL)-6-[(2S,5S)-5-HYDROXYMETHYLOXOLAN-2-YL]-5,6-DIHYDRO[1,3]-DIAZOLO[1,2-C][1,3]DIAZIN-5-ONE
• 英文别名: 6-[(2S,5S)-5-(hydroxymethyl)oxolan-2-yl]-2-(4-nitrophenyl)imidazo[1,2-c]pyrimidin-5-one
• CAS: 348597-64-8
• 化学式: C₁₇H₁₆N₄O₅
• 分子量: 356.338
• InChiKey: KLWATIKXJJFIBW-BBRMVZONSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Imidazopyrimidine nucleoside analogues with anti-HIV activity
  申请人：——

  公开号：US20020061896A1

  公开（公告）日：2002-05-23

  The present invention accordingly provides imidazopyrimidine nucleoside compounds of formula (I) 1 and a method for the treatment or prophylaxis of viral infections in mammals, including humans, comprising the step of administrating a therapeutically effective amount of said compound of formula (I), salts or esters of said compound, pharmaceutical acceptable derivatives or pharmaceutically acceptable salts or esters thereof. Further embodiments include the use of said nucleosides in the preparation of a medicament for the treatment of viral infections in mammals, a commercial packages and pharmaceutical formulations comprising said nucleosides as a therapeutically effective agents against an HIV infection.

  因此，本发明提供了式 (I) 的咪唑嘧啶核苷化合物 1 以及一种治疗或预防哺乳动物（包括人类）病毒感染的方法，该方法包括施用治疗有效量的所述式（I）化合物、所述化合物的盐或酯、药学上可接受的衍生物或其药学上可接受的盐或酯的步骤。进一步的实施方案包括使用所述核苷制备治疗哺乳动物病毒感染的药物、包含所述核苷的商业包装和药物制剂，作为抗 HIV 感染的治疗有效制剂。
• [EN] IMIDAZOPYRIMIDINE NUCLEOSIDE ANALOGUES WITH ANTI-HIV ACTIVITY<br/>[FR] ANALOGUES NUCLÉOSIDIQUES D'IMIDAZOPYRIMIDINE À ACTION ANTI-VIH
  申请人：IAF BIOCHEM INT

  公开号：WO2001049700A1

  公开（公告）日：2001-07-12

  The present invention accordingly provides imidazopyrimidine nucleoside compounds of formula (I) and a method for the treatment or prophylaxis of viral infections in mammals, including humans, comprising the step of administrating a therapeutically effective amount of said compound of formula (I), salts or esters of said compound, pharmaceutical acceptable derivatives or pharmaceutically acceptable salts or esters thereof. Further embodiments include the use of said nucleosides in the preparation of a medicament for the treatment of viral infections in mammals, a commercial packages and pharmaceutical formulations comprising said nucleosides as a therapeutically effective agents against an HIV infection.